JNJ | Weekly | Haru Insights

Johnson & Johnson (JNJ) delivered a strong Q2 2026 earnings beat with $2.90 in adjusted EPS and $25.31 billion in revenue, surpassing expectations and raising its full-year 2026 guidance to $100.8–101.4 billion in revenue and $11.55–$11.75 in adjusted EPS, signaling robust confidence in its innovation pipeline.
Despite overall earnings strength, the MedTech segment underperformed, with cardiovascular device sales declining sharply due to negative U.K. trial data from the PROTECT IV study on Abiomed’s Impella pumps, fueling investor skepticism and triggering a post-earnings stock dip.

JNJ’s Innovative Medicines segment is firing on all cylinders, with 72.5% growth in Tremfya and rapid adoption of Icotyde, proving its dermatology and oncology franchises are not just sustainable but explosively expanding.
The acquisition of Intra-Cellular Therapies and entry into neuroscience with Spravato and Caplyta is a strategic masterstroke, placing JNJ at the vanguard of the mental health treatment revolution with high-margin, pipeline-rich potential.
JNJ’s 64th consecutive dividend increase and $1.34 quarterly payout reaffirm its status as a rock-solid income generator, especially compelling in a high-rate environment where few peers match its combination of yield and consistency.
Strong revenue guidance revision to $100.8–101.4 billion reflects powerful momentum across multiple franchises, suggesting that JNJ’s innovation engine is not just working—it’s accelerating.
The resilience of non-immunology growth drivers like Tremfya and Icotyde shows JNJ is successfully outpacing the Stelara collapse, proving its ability to pivot and reinvest in high-growth therapeutic areas.

Johnson & Johnson (JNJ)[Tv]